These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 34003862

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK, Frederiksen JL, Nielsen HH, Torkildsen Ø, Eek C, Huang-Link Y, Haghighi S, Tsai JA, Kant M.
    Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T.
    JAMA Neurol; 2021 May 01; 78(5):558-567. PubMed ID: 33779698
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
    Tan H, Li X, Li Y, He F, ZhangBao J, Zhou L, Yang L, Zhao C, Lu C, Dong Q, Li H, Quan C.
    Front Immunol; 2024 May 01; 15():1343531. PubMed ID: 38558796
    [Abstract] [Full Text] [Related]

  • 27. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E, Joutseno J, Sumelahti ML.
    Clin Ther; 2017 Mar 01; 39(3):537-557.e10. PubMed ID: 28209373
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 01; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

  • 29. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb 01; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 30. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Hillert J, Tsai JA, Nouhi M, Glaser A, Spelman T.
    Mult Scler; 2022 Feb 01; 28(2):237-246. PubMed ID: 34080926
    [Abstract] [Full Text] [Related]

  • 31. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.
    J Neurol Neurosurg Psychiatry; 2019 Apr 01; 90(4):458-468. PubMed ID: 30636699
    [Abstract] [Full Text] [Related]

  • 32. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
    Earla JR, Li J, Hutton GJ, Bentley JP, Aparasu RR.
    Mult Scler Relat Disord; 2024 May 01; 85():105539. PubMed ID: 38574721
    [Abstract] [Full Text] [Related]

  • 33. Real-life use of oral disease-modifying treatments in Austria.
    Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).
    Acta Neurol Scand; 2019 Jul 01; 140(1):32-39. PubMed ID: 30958901
    [Abstract] [Full Text] [Related]

  • 34. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW, TOPIC Study Group.
    Lancet Neurol; 2014 Oct 01; 13(10):977-86. PubMed ID: 25192851
    [Abstract] [Full Text] [Related]

  • 35. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study.
    Condé S, Moisset X, Pereira B, Zuel M, Colamarino R, Maillet-Vioud M, Lauxerois M, Taithe F, Clavelou P, Réseau NeuroSEP Auvergne.
    Eur J Neurol; 2019 Mar 01; 26(3):460-467. PubMed ID: 30320947
    [Abstract] [Full Text] [Related]

  • 36. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
    Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, Amico E, Italian MS register.
    Mult Scler Relat Disord; 2022 Feb 01; 58():103489. PubMed ID: 35032879
    [Abstract] [Full Text] [Related]

  • 37. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R.
    J Neurol; 2020 Oct 01; 267(10):2790-2796. PubMed ID: 32494856
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.
    Lazzaro C, Bergamaschi R, Zaffaroni M, Totaro R, Paolicelli D.
    Neurol Sci; 2022 Aug 01; 43(8):4933-4944. PubMed ID: 35420360
    [Abstract] [Full Text] [Related]

  • 40. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC, ULTIMATE I and ULTIMATE II Investigators.
    N Engl J Med; 2022 Aug 25; 387(8):704-714. PubMed ID: 36001711
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.